Lacidipine
As of the edition of 20 October 2026, Lacidipine is a small molecule: marketed, first approved in 1993 (ES); acts on CACNA1C, CACNA1D and CACNA1F and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2003
- Kind
- Small molecule
- Brand name
- Lacipil
- First approved
- 1 April 1993 (ES)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- GSK
- Registered trials
- 12, 1 stopped early
- Disease areas
- Heart and blood vessels; Hormones; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 1 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 5 | 4 | 0 | 0 |
| All trials | 12 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Applicant and Lead sponsor of trials | 2003 to now |